HIV Infections Clinical Trial
Official title:
Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners
Project POWER will test the efficacy of a multi-session HIV Prevention program, adapted from an existing program (Project SAFE), for incarcerated women in the rural South.
Incarcerated women have a disproportionately high risk for both Sexually Transmitted
Infections (STIs) and Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome
(AIDS)and the prevalence of HIV and STIs are higher among women than men prisoners. More
than half of the HIV/AIDS cases reported by State and Federal prisons in 2005 were in the
South. The second highest regional burden for HIV among women released from correction
facilities is in the South.
Working in collaboration, the staff of the North Carolina Department of Correction (NCDOC)
and faculty at the University of North Carolina at Chapel Hill School of Nursing (SON),
School of Medicine (SOM), Center for AIDS Research (CFAR) and the School of Social Work
(SSW) will systematically adapt and test the efficacy of Project SAFE, an existing
evidence-based intervention (EBI), to increase protective behaviors, reduce high-risk
behaviors, and prevent STIs in HIV-negative incarcerated women in the Southern United
States.
Using Centers for Disease Control and Prevention (CDC) guidelines for adaptation (McKleroy,
Galbraith, Cummings et al. 2006), we will:
1. Assess the fit between intervention delivery and the needs and resources of the NCDOC
and the fit between intervention materials and the behavioral, social, and contextual
conditions of incarcerated women's lives following release from prison that may
contribute to continuing sexual risk behavior and explore their ideas regarding ways to
prevent STI/HIV with the intent of strengthening the approach to sexual risk reduction.
2. Adapt and tailor the Project SAFE behavioral risk reduction intervention for women
prisoners in the rural Southeastern U.S. who are HIV-negative and have sex with men.
3. Pilot the adapted Project SAFE intervention.
4. Test the adapted Project SAFE risk-reduction intervention with incarcerated women to
determine its efficacy in decreasing risk for non-viral STI infections (Chlamydia,
trichomoniasis or gonorrhea), decreasing sexual risk behaviors and increasing risk
reduction practices after release. We will also determine whether participants maintain
these changes over time.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |